[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-screening":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,41,67,99,128,152,178,208,233,253,278,307,329,349,373,407,428,452,473,496,514,538,558],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641198","kentucky---quality-improvement-implementation-lung-cancer-screening-quils-implementation-100641198",false,"NCT07639255","Kentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Implementation","Statewide Optimization of Lung Cancer Screening Utilizing the QUILS System","Inclusion Criteria:\n\n* Participants in Lung Cancer Screening Program, including physicians, nurses, administrators and other staff responsible for the conduct of the program.\n* Willing to participate in the QUILS Index Assessment Survey process\n* Willing to participate in the QUILS Audit Feedback presentations Willing to participate in formative evaluation interviews\n\nExclusion Criteria:\n\n* Unwilling to participate in the QUILS Index Assessment Survey process\n* Unwilling to participate in the QUILS Audit Feedback presentations\n* Unwilling to participate in formative evaluation interviews","ALL","18 Years","100 Years",{"count":20,"type":21},330,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with improved quality and retention of patients in the screening process. A feedback report is delivered to identify priorities for process improvement.",[27],"Lung Cancer Screening","RECRUITING","2026-06-27",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"2025-04-01",{"date":36,"type":21},"2028-06-01",{"name":38,"class":39},"Timothy Mullett","OTHER",17,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100557478","prediction-augmented-screening-initiative-100557478","NCT06538636","Prediction Augmented Screening Initiative","PASI","Inclusion Criteria:\n\nVeterans assigned a PCP at a participating site and who meet inclusion criteria at any point during the study timeframe will be enrolled into the trial. There will be two paths to patient inclusion:\n\n* meeting USPSTF eligibility criteria for LCS, as currently encoded in the background logic of LCS clinical reminders maintained by the VA National Center for Lung Cancer Screening (i.e., age 50-80 years; smoked 20 pack-years; current smoking or quit \\\u003C15 years ago) OR\n* predicted benefit calculated using LYFS-CTVA model exceeds a stringent high-benefit threshold of life-year gains with annual LCS, as recommended in the 2021 CHEST LCS guidelines\n\nExclusion Criteria:\n\n* Veterans who have previously undergone lung cancer screening, are diagnosed with lung cancer, or who do not meet eligibility criteria outlined above","50 Years","80 Years",{"count":51,"type":21},23520,[24],"Lung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer screening (LCS) finds cancer at an earlier stage when it is curable, yet only 20% of eligible Veterans have been screened. Uptake is even lower among Black Veterans despite higher lung cancer risk. Using prediction models to identify high-benefit people for whom LCS should be encouraged improves efficiency and reduces disparities. Moreover, it is more patient-centered as shared decision-making conversations can be tailored with personalized information. The US Preventive Services Task Force has called for research to demonstrate that prediction-augmented LCS can be feasibly implemented at the point-of-care. The investigators propose for VA to lead this effort with a large-scale pragmatic clinical trial to show that prediction-augmented LCS is both feasible and improves LCS uptake.",[55,27],"Lung Cancer","2026-06-23",{"date":58,"type":32},"2026-06-26",{"date":60,"type":32},"2026-06-01",{"date":62,"type":21},"2029-09-30",{"name":64,"class":65},"VA Office of Research and Development","FED",4,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":49,"enrollmentInfo":75,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100643349","ctdna-mutations-and-methylation-status-for-early-detection-of-lung-cancer-in-patients-with-suspicious-lung-nodules-100643349","NCT07615556","ctDNA Mutations and Methylation Status for Early Detection of Lung Cancer in Patients With Suspicious Lung Nodules","Circulating Tumor DNA Mutations and Methylation Status as Biomarkers for Early Detection of Lung Cancer in Patients With Suspicious Lung Nodules","Inclusion Criteria:\n\n1. Age 45 - 80 years;\n2. Suspicious lung nodules (\\> 0.5 - 30mm in longest diameter, non-calcified) found within the past six months, or if PET scan has been done before, the specific uptake value (SUV) should be more than 1\n\nExclusion Criteria:\n\n1. Age \\\u003C 45 or \\> 80;\n2. Lung nodules of \\\u003C 0.5 cm in longest diameter, or with calcification seen in imaging;\n3. Known lung cancer or lung metastasis before, or history of extra-pulmonary cancer;\n4. Active tuberculosis;\n5. Clinical unstable conditions including untreated ischemic heart disease or arrhythmia, uncontrolled airway disease;\n6. Unwillingness to undergo invasive investigation like bronchoscopy;\n7. Unable to provide informed written consent.","45 Years",{"count":76,"type":21},200,"2 Years","OBSERVATIONAL","Lung Cancer is common in Asia and is different from lung cancer from Western countries in terms of lung cancer epidemiology and management. Lung cancer can be detected early but most early-stage lung cancer appear as lung nodules with suspicious features on imaging. Workup and surveillance for subjects with suspicious lung nodule is a clinical problem. There is no consensus and clinical practice usually varies with local epidemiology of lung diseases namely the local clinical characteristics especially with lung cancer and pulmonary tuberculosis. The clinical challenge is to address whether pulmonary nodules identified on CT screening carry short- and long-term risk for lung cancer. The main objective of this study is to test the improvement of efficiency of diagnostic evaluation with clinical parameters and ctDNA mutation\u002Fmethylation profiling for artificial intelligence modeling of for early detection of lung cancer in subjects with suspicious lung nodules. The hypothesis is that ctDNA mutation and methylation will enhance early detection of lung cancer in patients with suspicious lung nodules. This is a longitudinal cohort study. A total of 200 subjects (100 from Hong Kong and 100 from Vietnam) with suspicious lung nodules on CT Thorax will be recruited. Blood samples will be collected at recruitment and subsequent 6 months follow up. ctDNA mutations and methylation with SPOTMAS Lung assays would be performed at baseline and at 6 months follow-up. The CT scan where the suspicious lung nodules were identified, will be used as baseline scan for recruitment. Recruited subjects will be arranged with a non-contrast LDCT scans at 6 months follow-up. The primary outcome measure of the study is the detection of ctDNA mutation and methylation in correlation with diagnosis of lung cancer or persistence of suspicious lung nodules. The secondary outcome measures of the study are the Sensitivity and specificity of clinical biomarkers in correctly identifying malignant lung nodule, i.e., lung cancer.",[81,27,82],"Lung Nodules","Suspected Lung Cancer",[84,85,86,87],"ctDNA mutation","Methylation status","Early detection of lung cancer","Suspicious lung nodules","NOT_YET_RECRUITING","2026-06-04",{"date":91,"type":32},"2026-06-08",{"date":93,"type":21},"2026-06",{"date":95,"type":21},"2028-12",{"name":97,"class":39},"The University of Hong Kong",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":116,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":98},"100643279","methylated-biomarkers-of-smoking-as-a-selection-tool-in-participants-for-lung-cancer-screening-100643279","NCT07631624","Methylated Biomarkers of Smoking as a Selection Tool in Participants for Lung Cancer Screening","MET-SELS","Cohort 1: Volunteers\n\nInclusion Criteria:\n\n* Age: Must be \\> 50 years of age\n* Smoking History: Includes individuals with and without a smoking history\n\nCohort 2: ZORALCS-study participants\n\nInclusion Criteria:\n\n* Age: 55-74 years old\n* Smoking History: Includes individuals with a smoking history",true,{"count":108,"type":21},1000,[24],"The MET-SELS study aims to revolutionize how we identify individuals for lung cancer screening by moving beyond the limitations of self-reported smoking history. Currently, eligibility for low-dose CT (LDCT) scans relies on \"pack-years\"-a metric often compromised by recall bias, under-reporting, and an inability to account for the biological nuances of smoke inhalation or environmental exposure. Consequently, current criteria miss nearly half of incidental lung cancers.\n\nTo bridge this gap, the study investigates DNA methylation as a stable, objective \"biological footprint\" of smoking. Unlike short-term biomarkers like nicotine or CO levels, specific epigenetic changes in genes such as AHRR and F2RL3 persist long after cessation and correlate accurately with cumulative tobacco exposure.\n\nLed by Professor Dr. Annemiek Snoeckx and a multidisciplinary team at UZA and the Centre for Medical Genetics, the research will analyze saliva samples from two groups: roughly 900 participants from the ZORALCS screening trial and 150 volunteers. By comparing saliva-derived genomic signatures against both self-reported data and professional interviews, the team aims to validate a panel of methylation markers that can pinpoint high-risk individuals with far greater precision.\n\nThe ultimate vision for MET-SELS is to implement a population-based \"saliva-first\" triage system, similar to the FIT test used for colorectal cancer. In this model, high-risk candidates would provide a saliva sample at home; only those with a confirmed epigenetic risk profile would be invited for a LDCT scan, significantly increasing the yield of early-stage lung cancer detection while streamlining healthcare resources.",[112,113,27,114,115],"Epigenetics","DNA Methylation","Risk Stratification With Biomarker","Saliva",[117,27,118,119,115],"DNA-methylation","Risk stratification","Smoking","2026-06-03",{"date":91,"type":32},{"date":123,"type":32},"2025-10-04",{"date":125,"type":21},"2028-01-01",{"name":127,"class":39},"University Hospital, Antwerp",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":98},"100573359","icare-lcs-queri-partnered-evaluation-initiative-integrating-comprehensive-tobacco-treatment-to-enhance-lung-cancer-screening-100573359","NCT06745258","ICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Tobacco Treatment to Enhance Lung Cancer Screening","ICARE-LCS QUERI Partnered Evaluation Initiative: Integrating Comprehensive Tobacco Treatment to Enhance Lung Cancer Screening (PEC 24-239)","ICARE-LCS","Inclusion Criteria:\n\n* This is a VAMC based Quality Improvement Partnered Evaluation Initiative. VA sites from around the country that agreed to participate are included.\n\nExclusion Criteria:\n\n* N\u002FA",{"count":137,"type":21},7,"Lung cancer is the leading cause of cancer-related death among Veterans with 90% of cases attributable to smoking. Lung cancer screening (LCS) combined with smoking cessation saves the most lives. ICARE-LCS seeks to decrease health inequality and improve Veteran health by reducing smoking rates among Veterans receiving LCS. ICARE-LCS will use implementation methods to inform national cancer prevention efforts and build infrastructure necessary to support broad implementation of high-impact tobacco dependence treatment (TDT) processes in LCS programs.",[140,27],"Tobacco Dependence Treatment",[55,142,143,27],"Lung Nodule","Tobacco","2026-05-21",{"date":146,"type":32},"2026-05-26",{"date":148,"type":21},"2026-10-01",{"date":150,"type":21},"2027-06-30",{"name":64,"class":65},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":174,"leadSponsor":176,"locationsCount":98},"100601549","evaluating-the-impact-of-connect-in-a-multilingual-population-100601549","NCT07111936","Evaluating the Impact of CONNECT in a Multilingual Population","Evaluating the Impact of CONNECT, a Novel Smoking Cessation Intervention, in a Diverse, Multilingual Population","CONNECT-ML","Inclusion Criteria:\n\n* Age 50-80 years old.\n* Current smokers defined at smoking at least one cigarette in past 7 days AND eligible for lung cancer screening (LCS) based on smoking history (\\>=20 pack year history)\n* California (CA) residents\n* Able to understand and comply with study procedures for the entire length of the study.\n* Ability of individual or legal guardian\u002Frepresentative to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n* Non-smokers.\n* Individuals with a diagnosis of lung cancer.\n* Individuals receiving hospice care.\n* Individuals whose providers do not think that they should participate (e.g., psychiatric illness or significant cognitive impairment that would impede the individuals ability to participate).\n* Hearing and\u002For vision disabilities that would prevent participants from adequately receiving treatment components such as video or telephone counseling.",{"count":161,"type":21},439,[24],"This study aims to broaden the reach of the lung cancer screening (LCS) CONNECT program (NCT04149249, NCT06213532), by developing a version of the program to be available to multilingual communities. The CONNECT program encourages individuals who are undergoing lung cancer screening to also quit smoking by providing a personalized program which includes a video doctor with personalized responses, text message and telephone call support and connection with a pharmacist to assist in obtaining nicotine replacement medication. This clinical trial will develop and ultimately test how well the CONNECT Multilingual (CONNECT ML) program works to improve smoking cessation among current adult smokers within the Spanish and Cantonese speaking communities.",[165,166,167,27],"Smoking Cessation","Smoking Cessation Counseling Ability and Practice","Smoking Cessation Counselling",[169],"Multilingual","2026-05-18",{"date":172,"type":32},"2026-05-22",{"date":31,"type":21},{"date":175,"type":21},"2028-03-31",{"name":177,"class":39},"University of California, San Francisco",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100640899","multilevel-intervention-for-ldct-lung-cancer-screening-and-smoking-cessation-among-african-americans-100640899","NCT07576595","Multilevel Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans","Effectiveness of a Multilevel Integrated Intervention for LDCT Lung Cancer Screening and Smoking Cessation Among African Americans","Inclusion Criteria:\n\n* African American\n* 20+ pack years of smoking\n* eligible for or received LDCT screening\n* current smoker\n* English speaking\n\nExclusion Criteria:\n\n* N\u002FA",{"count":186,"type":21},250,[24],"This study aims to reduce disparities and the burden of lung cancer among African American smokers by supporting a Multiple-level intervention integrating lung cancer screening and smoking cessation (MILS), followed the NIH DEIA strategies using multilevel interventions that impact determinants of health and address health disparities at appropriate time points across the life course.",[27,190,165],"Tobacco Use Disorder",[192,193,27,165,194,195,196,197],"African American","Health Disparities","Tobacco Use","Low-Dose Computed Tomography","LDCT","Behavioral Intervention","2026-05-07",{"date":200,"type":32},"2026-05-11",{"date":202,"type":32},"2025-04-17",{"date":204,"type":21},"2030-06",{"name":206,"class":39},"Louisiana State University Health Sciences Center in New Orleans",2,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100636479","increasing-lung-cancer-screening-among-emergency-department-patients---lcs-r01-100636479","NCT07566221","Increasing Lung Cancer Screening Among Emergency Department Patients - LCS R01","Increasing Lung Cancer Screening Uptake Among Emergency Department Patients - LCS R01","Inclusion Criteria:\n\n* Age 50 - 80\n* ≥ 20 pack-year smoking history\n* current smoker or quit within 15 years\n* English\u002FSpanish speaking\n* Registered in the Emergency Department as a patient\n\nExclusion Criteria:\n\n* Non-English\u002FSpanish\n* Inability to provide consent (e.g. high clinical acuity, cognitive deficit)\n* Lack of text-capable mobile phone and\u002For inability to use text function",{"count":216,"type":21},1036,[24],"This randomized clinical trial evaluates the effectiveness of text messaging and facilitated referral strategies to increase lung cancer screening uptake among emergency department patients who meet lung cancer screening eligibility criteria.",[220,221,27],"Smoking History","Current Smoker",[27,223,119],"Emergency Department","2026-04-28",{"date":226,"type":32},"2026-05-05",{"date":228,"type":21},"2027-03-01",{"date":230,"type":21},"2031-12-01",{"name":232,"class":39},"University of Rochester",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":207},"100624353","lung-07-advancing-precision-based-lung-cancer-screening-implementation-ai-guided-risk-stratification-and-biomarker-integration-crest-ai-100624353","NCT07408531","LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)","Inclusion Criteria:\n\n* Age 50-80 years at the time of consent\n* Meets at least one of the following LCS eligibility criteria:\n\n  * USPSTF: ≥20 pack-years, currently smoke or quit ≤15 years ago.\n  * Potter: 20 years of smoking, regardless of intensity\n  * ACS: ≥20 pack-years, no restriction on quit time\n* Receiving or scheduled for LDCT through the UI Health Lung Screening Program.\n* Willing to view a short (approximately 2-minute) educational video that explains Sybil AI scoring and LCS, complete the Sybil AI survey (if selected), and\u002For provide blood samples (optional).\n* Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC IRB ICF and HIPAA authorization.\n* Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.\n* As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study\n\nExclusion Criteria:\n\n* Inability to undergo LDCT\n* Current diagnosis or history of lung cancer \\\u003C 5 years prior to study enrollment.\n* Life expectancy \\\u003C1 year\n* Active lung infection requiring systemic therapy\n* Vulnerable population, including prisoners and pregnant or nursing women, will not be enrolled due to radiation exposure from LDCT, which is contraindicated in pregnancy.\n* Other major comorbidity, as determined by the study PI\n* Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.",{"count":240,"type":21},2500,[24],"This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.",[27],"2026-04-07",{"date":246,"type":32},"2026-04-13",{"date":248,"type":32},"2026-03-12",{"date":250,"type":21},"2038-02",{"name":252,"class":39},"University of Illinois at Chicago",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":207},"100633293","lung-cancer-screening-for-early-detection-of-suspicious-lung-nodules-in-latin-americalucas-latam-100633293","NCT07524803","Lung Cancer Screening for Early Detection of Suspicious Lung Nodules in Latin America(LUCAS-LATAM)","A Prospective Observational Study to Determine the Utility of Lung Cancer Screening for Early Detection of Suspicious Lung Nodules in Latin America","LUCAS-LATAM","Inclusion Criteria:\n\n1\\. Men and women ≥50 years of age and one of any of the following criteria:\n\n1. Exposure to wood smoke (at least 100 hours per year)\n2. A family history of lung cancer in first-degree relatives\n3. A diagnosis of COPD and\u002For emphysema\n4. Smokers with a tobacco index of 10 years or more\n\nExclusion Criteria:\n\n1. Lung cancer diagnosis or any other type of active cancer during the 5 years prior to the screening\n2. Incomplete clinical information\n3. Loss of 10% of the baseline weight during 6 months prior to study entry\n4. Having a functional status, psychiatric condition or comorbidity that precludes curative treatment\n5. Any situation that makes the subject ineligible for LDCT\n6. Life expectancy ≤5 years\n7. Subjects with previous history of pulmonary nodules.",{"count":262,"type":21},2000,"Prospective study to assess lung cancer screening with low dose CT scan (LDCT) in Latin America (LATAM) and prospectively evaluate chest-XRay analyzed with artificial intelligence (AI) using qXRin (QURE ai) at the initial visit correlating with the findins of the initial LDCT in patients with other high risk criteria to develop lung cancer. 2000 patients will be recruited in 4 LATAM countries (Mexico 700 pts, Costa Rica 300 pts, Colombia 500 pts, Argentina 500 pts). All patients will be ≥50years of age with one of the following additional inclusion criteria: a. exposure to wood smoke (at least 100 hours\u002Fyear), b.family history of lung cancer in a first degree relative, c. COPD and\u002For emphysema, d. smokers with a tobacco index of 10 y or more. The exclusion criteria include: a. lung cancer diagnosis or other type of cancer 5 years prior to screening, b. loss of 10% of baseline weight 6 months before inclusion, c. ineligible for LDCT, d. life expectancy ≤5 years, and e. previous history of pulmonary nodules.\n\nThe primary objective of the study is the utility of LDCT-based lung cancer screening in identifying suspicious lung nodules in smokers and non-smokers across LATAM, with secondary objectives including: 1- Utility of qXR-LNMS (lung nodule malignancy score) of chest XRay for lung cancer risk assessment to exclude low risk patients from LDCT screening, 2- Utility of LDCT-based lung cancer screening in subjects with various risk profiles in LATAM, 3- Prevalence of lung nodules in the study population, 4-Mortality rate in the subjects diagnosed with an anomaly in the LDCT (with or without LC diagnosis).",[27],[266,267,268,269],"lung cancer","screening","low dose CT scan","lung nodule","2026-04-06",{"date":246,"type":32},{"date":273,"type":21},"2026-05-01",{"date":275,"type":21},"2032-05-01",{"name":277,"class":39},"Latin American Consortium for the Lung Cancer Research",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":285,"minAge":48,"maxAge":286,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":292,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":98},"100454272","lung-cancer-screening-with-low-dose-ct-scan-in-women--implementation-study-100454272","NCT05195385","Lung Cancer Screening With Low-dose CT Scan in Women : Implementation Study","CASCADE","Inclusion Criteria:\n\n* Women aged from 50 to 74 years\n* who had smoked at least 20 pack years and quit less than 15 years ago\n* Had given their consent and accepted the need for a 2-year follow-up\n* Affiliated to the social security system\n\nExclusion Criteria\n\n* Presence of clinical symptoms suggesting malignancy (weight loss, hemoptysis) or ongoing infection (cough with fever)\n* Evolving cancer\n* History of lung cancer\n* A 2-year follow-up not possible\n* Chest CT scan performed within 2 years prior to inclusion","FEMALE","74 Years",{"count":288,"type":21},2635,[24],"The purpose of this study is to determine whether reading of low-dose thoracic CT scans can be done by a single general radiologist who has been trained to lung cancer screening, and will evaluate the performance in comparison with double reading by experts.\n\nThe study will enroll women between 50 and 74 years old, at risk for lung cancer due to their smoking history.",[27],[293,294,295,296,297],"lung neoplasms","multidetector computed tomography","early detection of cancer","artificial intelligence","lung cancer screening","2026-03-25",{"date":300,"type":32},"2026-03-30",{"date":302,"type":32},"2022-04-08",{"date":304,"type":21},"2027-10-08",{"name":306,"class":39},"Assistance Publique - Hôpitaux de Paris",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":326,"leadSponsor":328,"locationsCount":98},"100629752","assessing-the-effectiveness-of-low-dose-computed-tomography-in-lung-cancer-screening-for-high-risk-smokers-a-randomized-controlled-trial-in-hong-kong-100629752","NCT07478757","Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized Controlled Trial in Hong Kong","Inclusion Criteria:\n\n1. Adults aged between 50 and 79 years\n2. Current smokers or ex-smokers quitted for less than 10 years, with a history of cigarette smoking equivalent to at least 20 pack-years\n\nExclusion Criteria:\n\n1. Non-Chinese population\n2. Individuals who are not mentally competent to provide informed consent (e.g., those with a history of dementia)\n3. Individuals with a known prior diagnosis of lung cancer or detection of lung nodules\n4. Individuals with a history of other cancers within the last five years or currently under treatment\n5. Individuals who have undergone a CT scan of the thorax in the previous 12 months\n6. Individuals who are either unwilling to undergo a chest LDCT scan, or having a condition that prevents them from having a LDCT scan (for example, pregnancy or inability to lie flat on the CT table)","79 Years",{"count":315,"type":21},15000,[24],"The investigators propose a randomized controlled trial to evaluate the clinical effectiveness of low-dose computed tomography (LDCT) for lung cancer screening in high-risk Chinese ever-smokers aged 50-79 years in Hong Kong and to assess the cost-effectiveness of implementing LDCT for lung cancer screening in the local setting.",[55,27],[55,320,321,322],"Low-dose computed tomography (LDCT)","Screening","High-risk smokers",{"date":324,"type":32},"2026-03-17",{"date":31,"type":21},{"date":327,"type":21},"2037-06-30",{"name":97,"class":39},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":98},"100610430","advancing-lung-cancer-screening-one-text-at-a-time-100610430","NCT07227480","Advancing Lung Cancer Screening One Text at a Time","Inclusion Criteria:\n\n* 50 to 80 years old\n* have not completed their annual screening for lung cancer\n* have a 20 pack-year smoking history\n* currently smoke or have quit within the past 15 years\n* speak English and\u002For Spanish\n* have a functioning cellphone number with unlimited text messaging capacity\n* be willing to complete a baseline and a follow-up (at Month 3) survey\n\nExclusion Criteria:\n\n* being up-to-date on their annual lung cancer screening",{"count":336,"type":21},40,[24],"The purpose of this study is to assess the feasibility, acceptability, and preliminary impact of text messaging to promote lung cancer screening.",[27],[27],"2026-02-16",{"date":343,"type":32},"2026-02-19",{"date":345,"type":32},"2026-02-17",{"date":347,"type":21},"2026-08",{"name":232,"class":39},{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":356,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":372},"100571214","a-study-of-lung-cancer-screening-in-people-with-unexplained-weight-loss-100571214","NCT06717334","A Study of Lung Cancer Screening in People With Unexplained Weight Loss","Enrichment of Lung Cancer Screening Through Unexplained Weight Loss (UWL) to Stage Shift and Improve Survival","Inclusion Criteria:\n\n* Eligible for American Cancer Society lung cancer screening, as follows:\n\n  * Age 50-80 years old\n  * At least 20-pack year history of smoking\n* Weight loss of 3-10%, defined as UWL, within any timeframe over the past in the 18 months prior to enrollment, that cannot be attributed to an underlying medical condition at the discretion of the enrolling investigator\n\n  * Note that patients who have 3-10% weight may still be enrolled if the enrolling investigator does not conclude that the weight loss can be attributed to the patient's intentional efforts.\n  * Documented weight loss can be self-reported or extracted from weights obtained during physician visits. However, if self-reported weight loss is contradicted by weight loss documented in the medical record (e.g. a patients states that (s)he lost 10 lbs in the past 6 months, but a weight documented in the medical record does not support that history), the measured and quantified weight change will be used to ascertain eligibility\n* Life expectancy greater than 1 year, per assessment of the treating clinician.\n\nExclusion Criteria:\n\n* Currently pregnant or trying to become pregnant via self-report\n* Prior history of recent CT scan of the chest either through LDCT screening or with a scan of the chest (standard, not LDCT) performed within the past 12 months\n* Prior history of NSCLC\n\n  ○ Note that patients with a history of diagnosis of non-lung cancers are eligible for the study.\n* Currently undergoing or referred for diagnostic evaluation due to clinical suspicion for malignancy (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).\n* Patients with a germline pathogenic genetic variant who have undergone whole body MRI within the past 12 months\n* Unable to comply with study procedures",{"count":357,"type":21},409,"The researchers are doing this study to see if people with unexplained weight loss who have lung cancer screening are more likely to have or develop lung cancer than people without unexplained weight loss. The lung cancer screening will involve use of low-dose computed tomography (LDCT), a CT scan that gives off very low doses of radiation and can make detailed pictures of the lungs to help find tumors. The study researchers will also analyze participants' blood samples to determine if blood testing can be used to help to diagnose lung cancer.",[27],[361,362],"ctDNA analysis","Low dose computed tomography (CT)","2026-01-21",{"date":365,"type":32},"2026-01-23",{"date":367,"type":32},"2024-12-02",{"date":369,"type":21},"2026-12",{"name":371,"class":39},"Memorial Sloan Kettering Cancer Center",8,{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":381,"maxAge":313,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":389,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":98},"100616121","akershus-cardiac-examination-ace-5-study-100616121","NCT07301489","Akershus Cardiac Examination (ACE) 5 Study","Akershus Cardiac Examination (ACE) 5 Study: Pragmatic Randomized Controlled Trial of Lung Cancer Screening Plus Program to Improve Cardiovascular Risk Profile and Health in Individuals With Heavy Smoking History","ACE5","Inclusion Criteria used for the lung cancer screening implementation study\u002F TIDL Study:\n\n* Women and men\n* Ages 60 to 79 years old (inclusive)\n* A smoking history of at least 35 pack-years and 1) being a current smoker or a former smoker who quit less than 10 years prior or 2) having a PLCOm2012 model 6-year risk for lung cancer incidence over 2.6%.\n* Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures\n* Written informed consent obtained prior to performing any protocol-related procedures\n* The participant should be affiliated to a social security system\n\nExclusion Criteria used for the lung cancer screening implementation study\u002F TIDL Study:\n\n* Recent abnormal pulmonary findings under work-up of standard care\n* Having had chest CT \\\u003C1 year before potential entry into the study\n* Current or prior history of lung cancer, renal cancer, melanoma or breast cancer\n* Inability to provide signed informed consent\n* Insufficient understanding of the languages in which trial information is available\n* Psychiatric or other disorders that are incompatible with compliance to the protocol requirements and follow-up\n* Unable to be followed-up for at least 5-years\n* Body weight \\>140 Kg because of difficulty of conducting the CT exam\n\nInclusion Criteria used for the ACE 5 Study:\n\n* Participants from the TIDL Study with non-contrast, non-cardiac chest CT images available as part of the implementation lung cancer screening study\n* Signed consent for cardiovascular add on-study and agree to protocol, including follow-up visit 1-year after the baseline examination\n\nExclusion Criteria used for the ACE 5 Study:\n\n* Any surgical or medical condition, including short life-expectancy, based on medical records or clinical findings prior to randomization, that will impair the ability of the patient to participate in the study\n* Patients unwilling or unable to comply with the protocol\n* History of non-compliance to medical management and patients who are considered potentially unreliable, based on information obtained prior to randomization\n* History or evidence of alcohol or drug abuse with the last 12 months, based on information obtained prior to randomization, that will influence study participation","60 Years",{"count":108,"type":21},[24],"Individuals with extensive smoking history have 2- to 3-fold increased risk of dying prematurely compared to age- and gender-matched peers. Historical data indicate that 55% of heavy smokers will die from cardiovascular disease (CVD), while approximately 5% will die from lung cancer. Lung cancer screening programs are currently being implemented worldwide, but efforts to reduce also CVD are not included.\n\nThe research group behind the ACE 5 Study are affiliated with the study team behind the implementation study of lung cancer screening in Norway (\"Tidlig oppdagelse av lungekreft \\[TIDL\\]\"). The TIDL Study have performed non-contrast, non-cardiac chest CT-based screening for lung cancer in 1000 individuals. Prior studies have demonstrated that a visual four-group classification of coronary artery calcification using non-contrast, non-cardiac chest CT images provide an easily available, non-invasive surrogate index for subclinical and established chronic coronary syndrome. Accordingly, the 2024 European Society of Cardiology guidelines for chronic coronary syndrome promotes that opportunistic screening for atherosclerotic CVD (ASCVD) should be performed when non-contrast, non-cardiac chest CT images are available (\"IIa recommendation\"). The investigators will now invite TIDL participants for a second study, the Akershus Cardiac Examination (ACE) 5 Study, which will assess whether intervention also against ASCVD (\"Lung Cancer Screening Plus Program\") will improve cardiovascular risk profile and cardiovascular health in individuals with heavy smoking history.\n\nThe ACE 5 Study will be a separate study with separate protocol and consent as the ACE 5 Study will focus on the prevention of CVD in individuals with heavy smoking history as add-on to lung cancer screening. The ACE 5 Study will assess the combined effect of (1) non-contrast, non-cardiac chest CT images as basis for ASCVD detection, and (2) the value of a hospital-based, nurse-led follow-up program to improve cardiovascular risk profile and cardiovascular health in individuals with heavy smoking history. Whether a Lung Cancer Screening Plus Program can improve cardiovascular risk profile and indices of improved cardiovascular health compared to the current strategy\u002Fstandard in individuals with heavy smoking history is currently not known. The primary endpoint relates to status for cardiovascular risk profile after 1-year follow-up, and the study will use pre-defined cutoffs for the different risk factors based on relevant European Society of Cardiology (ESC) Guidelines, especially the 2021 ESC guidelines for primary prevention and the 2024 ESC guidelines for chronic coronary syndrome.",[386,27,387,388],"Heavy Smokers","Cardiovascular Risk Profile","Cardiovascular Disease Prevention",[390,391,392,393,394,395,396,397],"Heavy smokers","Lung cancer screening","Cardiovascular risk profile","Cardiovascular disease prevention","Chronic coronary syndrome","Atherosclerotic cardiovascular disease","Non-contrast, non-cardiac chest CT-based screening","Nurse-led follow-up program","2025-12-10",{"date":400,"type":32},"2025-12-24",{"date":402,"type":32},"2025-10-01",{"date":404,"type":21},"2041-04",{"name":406,"class":39},"University Hospital, Akershus",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":424,"leadSponsor":426,"locationsCount":4},"100586023","community-based-engagement-to-improve-lung-cancer-screening-and-outcomes-the-our-lungs-our-health-study-100586023","NCT06909981","Community-Based Engagement to Improve Lung Cancer Screening and Outcomes: The \"Our Lungs Our Health\" Study","Community-Based Engagement to Improve Lung Cancer Screening and Outcomes","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document prior to any study-related procedures.\n* Willing to undergo treatment.\n* Adults between the ages of 50 and 80 years.\n* No recent CT imaging within the last year.\n* Currently smokes tobacco or has quit smoking tobacco within the past 15 years.\n* Has a tobacco smoking history of at least 20 pack years (i.e. one pack per day for the last 20 years or equivalent).\n* Has never been diagnosed with lung cancer.\n\nExclusion Criteria:\n\n* Adults\u002Fchildren less than 50 years, or greater than 80 years of age.\n* Has never smoked tobacco.\n* Has smoked tobacco but quit more than 15 years ago.\n* Has a tobacco smoking history of less than 20 pack years.\n* Presence of major comorbidity(ies) that could prevent treatment.\n* Previous diagnosis of lung cancer.\n* In the opinion of the investigator, the subject is not an appropriate candidate for the study.",{"count":415,"type":21},125,[24],"The main goal of this pilot study is to understand the impact of a mobile lung cancer screening clinics in individuals from neighborhoods and communities with less access to resources in Boston, Massachusetts who are at high risk for lung cancer. A secondary goal of this pilot study is to understand how social determinants of health impact these neighborhoods and communities. Another secondary goal of this pilot study is to see if video recording of participants speaking to their future selves and sending the videos back to participants to encourage them to get lung cancer screening after one year can be administered in a mobile lung cancer screening setting. The questions this study aims to answer are:\n\n* Is mobile lung cancer screening is feasible and acceptable?\n* Is collecting social needs data during the mobile lung cancer screening clinics feasible?\n* Is creating video recordings of patients encouraging their future selves to get lung cancer screening after one year feasible?\n\nParticipants will:\n\n* Complete an intake survey, providing information about their demographic, medical, and social needs information.\n* Undergo a shared decision-making conversation to determine whether lung cancer screening should be done.\n* Undergo lung cancer screening.\n* Undergo a debriefing conversation and fill out an acceptability survey.\n* Record a video speaking to their future selves about the importance of annual lung cancer screening, with the video to be sent back to them after roughly one year.\n* Undergo a semi-structured phone interview between four and eight weeks after lung cancer screening date.",[27],[27],"2025-12-02",{"date":422,"type":32},"2025-12-08",{"date":273,"type":21},{"date":425,"type":21},"2026-11-01",{"name":427,"class":39},"Brigham and Women's Hospital",{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":433,"acronym":4,"eligibilityCriteria":434,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":435,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":98},"100602677","validation-of-the-spot-mas-lung-test-using-circulating-tumor-dna-for-the-detection-of-lung-cancer-100602677","NCT07126626","Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer","Multi-center Prospective Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer","Inclusion Criteria:\n\nCohort A\n\n1. Volunteers (participants) aged 50-80 years at the time of consent.\n\n   1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.\n   2. 50% never-smokers or light smokers (\\\u003C 20 pack-years or quit \\> 15 years) who are first- or second-degree relatives of LC patients.\n2. Willing to undergo LDCT\u002FNCCT of the chest for lung cancer screening.\n3. Willing to consent to an investigational blood draw during the index LDCT\u002FNCCT screening visit and before any invasive procedures or treatment for lung cancer diagnosis.\n4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.\n\nCohort B\n\n1. Subjects aged 50-80 years at the time of consent.\n\n   1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.\n   2. 50% never-smokers or light smokers (\\\u003C 20 pack-years or quit \\> 15 years) who are first- or second-degree relatives of LC patients.\n2. Have undergone LDCT\u002FNCCT of the chest for lung cancer screening\u002Fdiagnosis, including only high-risk lesions (LUNG-RADS 4).\n3. Willing to consent to an investigational blood draw before any invasive procedures (CECT\u002FPET-CT\u002Fbiopsy) or treatment for lung cancer diagnosis.\n4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.\n\nExclusion Criteria for both Cohort A and Cohort B\n\n1. Subject has a health problem that substantially limits life expectancy and\u002For the ability or willingness to have curative lung surgery.\n2. Subject is undergoing CECT for investigation of highly suspicious symptoms for lung cancer.\n3. Pre-existing or history of lung cancer.\n4. History of any malignancy (subjects who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study).\n5. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.\n6. Currently receiving treatment for pneumonia.\n7. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent.\n8. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study.\n9. Participation in a clinical research study in which an experimental medication and\u002For medical procedure has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of subject screening.\n\n   \\-\n\n   Exclusion Criteria:\n\n   \\-",{"count":436,"type":21},1184,"This is an observational clinical trial, aiming to evaluate the efficacy of the SPOTMAS LUNG (SML) test compared to Low dose CTScan (LDCT)\u002FNone contrast CTScan (NCCT) in two distinct risk populations:\n\n* Cohort A: To demonstrate that SML is concordant with LDCT\u002FNCCT in general population lung cancer screening, including low-risk (LRs0-1-2), intermediate-risk (LRs3), and high-risk (LRs4) groups.\n* Cohort B: To validate the sensitivity and specificity of SML in the high-risk group (LRs4).",[439,27],"Lung Diseases",[441],"SPOT-MAS Lung Test","2025-08-10",{"date":444,"type":32},"2025-08-17",{"date":446,"type":21},"2025-08-18",{"date":448,"type":21},"2027-07-31",{"name":450,"class":451},"Gene Solutions","INDUSTRY",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":106,"sex":16,"minAge":458,"maxAge":286,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100598941","a-randomized-controlled-trial-evaluating-the-effectiveness-of-a-novel-risk-stratified-screening-strategy-for-lung-cancer-100598941","NCT07078032","A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Risk-Stratified Screening Strategy for Lung Cancer","Inclusion Criteria:\n\n1. Residents with local household registration residing continuously in the region for ≥3 years.\n2. Aged 40-74 years at enrollment.\n\nExclusion Criteria:\n\n1. Prior diagnosis of lung cancer (histologically\u002Fcytologically confirmed)\n2. Currently receiving active treatment for any malignancy.\n3. Presence of severe comorbidities with life expectancy \\\u003C5 years\n4. Participation in any lung cancer screening program within 5 years.\n5. Functional dependency (ADL score ≤2) OR unwillingness to comply with protocol-required follow-up.\n6. Declined to provide written informed consent.","40 Years",{"count":460,"type":21},60000,[24],"A nationwide population-based multi-center RCT enrolling ≥60,000 eligible residents to compare screening effectiveness between risk-prediction-model-driven and traditional guideline-based high-risk lung cancer screening strategies.",[27],"2025-07-12",{"date":466,"type":32},"2025-07-22",{"date":468,"type":21},"2025-07",{"date":470,"type":21},"2028-11",{"name":472,"class":39},"The First Affiliated Hospital of Guangzhou Medical University",{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":106,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":98},"100593609","signature-development-and-validation-protocol-for-an-epigenetic-assay-in-diagnosing-lung-cancer-100593609","NCT07008664","Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer","Inclusion Criteria:\n\n* 18 years old or older\n* Patient at University of Maryland Baltimore Washington Medical Center\n* Willing and able to consent to study procedures listed in the protocol\n* Ability to speak and understand English\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Patient not cared for at University of Maryland Baltimore Washington Medical Center\n* Unable to consent to study procedures listed in the protocol\n* Unable to speak or understand English",{"count":480,"type":21},750,"The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.\n\nParticipants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.",[55,27,483,484],"Healthy Volunteers (HV)","Unhealthy Volunteers",[55,27,486,484],"Healthy Volunteers","2025-06-05",{"date":489,"type":32},"2025-06-11",{"date":491,"type":32},"2025-03-31",{"date":493,"type":21},"2032-04",{"name":495,"class":39},"University of Maryland, Baltimore",{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":106,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":502,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":504,"conditions":505,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":98},"100583161","cprit-patient-adherence-to-lung-cancer-screening-100583161","NCT06872723","CPRIT: Patient Adherence to Lung Cancer Screening","Inclusion Criteria:\n\n* Current smoker or quit within the past 15 years\n* A 20+ pack-year smoking history\n* Healthy enough for treatment\n\nExclusion Criteria:\n\n* Not applicable as our focus is on patients with an order for screening at the UTMB or UT Tyler",{"count":503,"type":21},340,"To understand participants' barriers to lung cancer screening and their experience with scheduling lung cancer screening.",[27],{"date":507,"type":32},"2025-04-02",{"date":509,"type":32},"2025-03-21",{"date":511,"type":21},"2031-02-28",{"name":513,"class":39},"M.D. Anderson Cancer Center",{"id":515,"slug":516,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":524,"conditions":525,"keywords":526,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":98},"100550742","prevention-of-smoking-related-diseases-100550742","NCT06451029","Prevention of Smoking Related Diseases","Integrated Primary and Secondary Prevention of Smoking Related Diseases With Low Dose CT Scan and Circulating Biomarkers, Coupled With Personalised Smoking Cessation Activity","LSP-3","Inclusion Criteria:\n\n* Strong smokers (pack years \\>= 20)\n* Over or equal the age of 50\n* Able to sign specific informed consent for the study\n\nExclusion Criteria:\n\n* Not having plans to quit smoking",{"count":523,"type":21},189,"This is a prospective, observational, monocentric study. This study wants to test if among a smoking cessation intervention, behavioural counselling by video session is related to higher compliance and higher success rate than standard smoking cessation activity (face to face counselling).",[55,27,165],[297,527,528],"smoking cessation","counseling","2024-11-26",{"date":531,"type":32},"2024-11-29",{"date":533,"type":32},"2022-01-11",{"date":535,"type":21},"2025-12-31",{"name":537,"class":39},"Scientific Institute San Raffaele",{"id":539,"slug":540,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":22,"phases":546,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":98},"100556917","advancing-lung-cancer-screening-artificial-intelligence-multimodal-imaging-and-cutting-edge-technologies-for-early-detection-and-characterization-100556917","NCT06531343","Advancing Lung Cancer Screening: Artificial Intelligence, Multimodal Imaging and Cutting-Edge Technologies for Early Detection and Characterization","Inclusion Criteria:\n\n* Age \\> 50 years\n* PLCOm2012 risk prediction \\> 4%\n* Be willing to adhere to the study intervention through \\[18F\\]FDG PET\u002FCT or LDCT imaging\n* Signed written informed consent form\n\nExclusion Criteria:\n\n* Blood glucose levels \\>200 mg\u002Fdl,\n* Ongoing pregnancy and breastfeeding\n* Unwillingness to participate,\n* Previous diagnosis of lung cancer,\n* Previous CT scan within the last 24 months\n* Concomitant severe clinical conditions and any condition that preclude the feasibility of the study",{"count":545,"type":21},334,[24],"Currently available screening programmes for lung cancer are limited by many challenges including low diagnostic accuracy, radiation exposure and high costs. New technologies in PET\u002FCT scanners can allow cheaper and more sensitive exams with low radiation exposure. AI can be used to denoise LDCT to enhance the accuracy of imaging tests and build riskassessment models. This project aims to develop a new approach exploiting both these revolutionary advancements to bridge the existing gap in lung cancer screening. Patients in a high-risk population will be enrolled into two different cohorts undergoing LDCT scan and simultaneous \\[18F\\]FDG PET\u002FCT on new-generation long axial field of view scanner (UO1) or screening with low LDCT only (UO2). AI will assist in image enhancement and interpretation and will develop a personalised risk-model guiding the following steps of clinical management, significantly improving early diagnosis of lung cancer, reducing mortality and healthcare costs.",[27],"2024-10-18",{"date":551,"type":32},"2024-10-21",{"date":553,"type":21},"2024-10-30",{"date":555,"type":21},"2026-08-30",{"name":557,"class":39},"IRCCS San Raffaele",{"id":559,"slug":560,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":106,"sex":16,"minAge":458,"maxAge":49,"enrollmentInfo":565,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":581},"100552498","understanding-lung-cancer-related-risk-factors-and-their-impact-100552498","NCT06473870","Understanding Lung Cancer Related Risk Factors and Their Impact","LUCIA","Inclusion Criteria (for the 3 phases):\n\n* Subjects aged between 40 and 80 years\n* Both genders, of which at least 37% must be women to ensure representativeness\n* Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures\n* Written informed consent obtained prior to performing any protocol-related procedures.\n\nInclusion criteria for Phase 2: Precision Screening:\n\n* High risk of developing Lung Cancer volunteers will be selected by Lung Cancer risk factors modelling.\n\nInclusion criteria for Phase 3: Diagnosis:\n\n\\- Patients diagnosed with indeterminate pulmonary nodules or Lung Cancer from the screening phases.\n\nExclusion Criteria:\n\n* Subjects under 40 years of age\n* Unable to be followed-up for at least 2-years or complete the study\n* Subjects that do not sign the informed consent\n* Current or prior history of lung cancer\n* History of neoplasia in the previous 5 years except non-melanoma skin cancer\n* Moderate-severe comorbidities that prevent completion of a diagnostic study in the event of findings suggestive of lung neoplasia (by means of the investigator's clinical judgment) or surgical intervention (\\\u003C 6 months) if not previously confirmed by cytohistology.\n* Vulnerable subjects: severe psychiatric comorbidity, adults under guardianship or deprived of liberty\n* Pregnant women",{"count":566,"type":21},6160,"LUCIA aims to develop prediction models for the early diagnosis of lung cancer based on the identification of risk factors and deeper cellular knowledge, by recording real-world data; with risk assessment tools, non-invasive devices and omics analysis. These models will enable new clinical pathways and diagnostic workflow to be implemented to ensure early diagnosis and confirmation, including classification of lung cancer subtype.",[27],[55,391,196,570],"Risk factors","2024-06-19",{"date":573,"type":32},"2024-06-25",{"date":575,"type":21},"2024-07",{"date":577,"type":21},"2027-12",{"name":579,"class":580},"Biobizkaia Health Research Institute","OTHER_GOV",5]